Skip to main content
AAN.com

Abstract

Objective: To investigate whether cognitive slowing in Parkinson disease (PD) reflects disruption of the basal ganglia or dysfunction of the frontal lobe by excluding an influence of abnormal brain activity due to motor deficits.
Methods: We measured neuronal activity during a verbal mental-operation task with H215O PET. This task enabled us to evaluate brain activity change associated with an increase in the cognitive speed without an influence on motor deficits.
Results: As the speed of the verbal mental-operation task increased, healthy controls exhibited proportional increase in activities in the anterior striatum and medial premotor cortex, suggesting the involvement of the corticobasal ganglia circuit in normal performance of the task. By contrast, patients with PD lacked an increase in the striatal activity, whereas the medial premotor cortex showed a proportional increase.
Conclusions: Although the present study chose a liberal threshold and needs subsequent confirmation, the findings suggest that striatal disruption resulting in abnormal processing in the corticobasal ganglia circuit may contribute to cognitive slowing in Parkinson disease, as is the case in motor slowing.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (e1.doc)

References

1.
Owen AM, Doyon J, Dagher A, Sadikot A, Evans AC. Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions. Brain 1998;121:949–965.
2.
Dagher A, Owen AM, Boecker H, Brooks DJ. The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease. Brain 2001;124:1020–1032.
3.
Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 2003;23:6351–6356.
4.
Mattay VS, Tessitore A, Callicott JH, et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 2002;51:156–164.
5.
Monchi O, Petrides M, Doyon J, Postuma RB, Worsley K, Dagher A. Neural bases of set-shifting deficits in Parkinson's disease. J Neurosci 2004;24:702–710.
6.
Sawamoto N, Honda M, Hanakawa T, Fukuyama H, Shibasaki H. Cognitive slowing in Parkinson's disease: a behavioral evaluation independent of motor slowing. J Neurosci 2002;22:5198–5203.
7.
Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997;41:58–64.
8.
Berardelli A, Rothwell JC, Thompson PD, Hallett M. Pathophysiology of bradykinesia in Parkinson's disease. Brain 2001;124:2131–2146.
9.
Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357–381.
10.
Pate DS, Margolin DI. Cognitive slowing in Parkinson's and Alzheimer's patients: distinguishing bradyphrenia from dementia. Neurology 1994;44:669–674.
11.
Carlin D, Bonerba J, Phipps M, Alexander G, Shapiro M, Grafman J. Planning impairments in frontal lobe dementia and frontal lobe lesion patients. Neuropsychologia 2000;38:655–665.
12.
Hanakawa T, Honda M, Sawamoto N, et al. The role of rostral Brodmann area 6 in mental-operation tasks: an integrative neuroimaging approach. Cereb Cortex 2002;12:1157–1170.
13.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
14.
Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme Medical, 1988.
15.
Evans AC, Collins DL, Mills SR, Brown ED, Kelly RL. 3D statistical neuroanatomical models from 305 MRI volumes. In: Proc IEEE-Nucl Sci Symp Med Imaging, 1993:1813–1817.
16.
Timmer J, Lauk M, Deuschl G. Quantitative analysis of tremor time series. Electroencephalogr Clin Neurophysiol 1996;101:461–468.
17.
Deuschl G, Krack P, Lauk M, Timmer J. Clinical neurophysiology of tremor. J Clin Neurophysiol 1996;13:110–121.
18.
Picard N, Strick PL. Motor areas of the medial wall: a review of their location and functional activation. Cereb Cortex 1996;6:342–353.
19.
Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876–880.
20.
Bischoff-Grethe A, Martin M, Mao H, Berns GS. The context of uncertainty modulates the subcortical response to predictability. J Cogn Neurosci 2001;13:986–993.
21.
Poldrack RA, Sabb FW, Foerde K, et al. The neural correlates of motor skill automaticity. J Neurosci 2005;25:5356–64.
22.
Marsden CD. The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology 1982;32:514–539.
23.
Selemon LD, Goldman-Rakic PS. Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey. J Neurosci 1985;5:776–794.
24.
Schultz W, Apicella P, Romo R, Scarnati E. Context-dependent activity in primate striatum reflecting past and future behavioral events. In: Houk JC, Davis JL, Beiser DG, eds. Models of information processing in the basal ganglia. Cambridge MA: MIT Press, 1995:11–27.
25.
Braver TS, Cohen JD, Nystrom LE, Jonides J, Smith EE, Noll DC. A parametric study of prefrontal cortex involvement in human working memory. Neuroimage 1997;5:49–62.
26.
Rypma B, Prabhakaran V, Desmond JE, Glover GH, Gabrieli JD. Load-dependent roles of frontal brain regions in the maintenance of working memory. Neuroimage 1999;9:216–226.
27.
Fry AF, Hale S. Relationships among processing speed, working memory, and fluid intelligence in children. Biol Psychol 2000;54:1–34.
28.
Turner RS, Grafton ST, Votaw JR, Delong MR, Hoffman JM. Motor subcircuits mediating the control of movement velocity: a PET study. J Neurophysiol 1998;80:2162–2176.
29.
Taniwaki T, Okayama A, Yoshiura T, et al. Reappraisal of the motor role of basal ganglia: a functional magnetic resonance image study. J Neurosci 2003;23:3432–3438.
30.
Inase M, Tokuno H, Nambu A, Akazawa T, Takada M. Corticostriatal and corticosubthalamic input zones from the presupplementary motor area in the macaque monkey: comparison with the input zones from the supplementary motor area [erratum appears in Brain Res 2000;861:190]. Brain Res 1999;833:191–201.
31.
Tanaka S, Honda M, Sadato N. Modality-specific cognitive function of medial and lateral human Brodmann area 6. J Neurosci 2005;25:496–501.
32.
Mendez MF, Adams NL, Lewandowski KS. Neurobehavioral changes associated with caudate lesions. Neurology 1989;39:349–354.
33.
Cromwell HC, Berridge KC. Implementation of action sequences by a neostriatal site: a lesion mapping study of grooming syntax. J Neurosci 1996;16:3444–3458.
34.
Schultz W, Romo R. Role of primate basal ganglia and frontal cortex in the internal generation of movements. I. Preparatory activity in the anterior striatum. Exp Brain Res 1992;91:363–384.
35.
Playford ED, Jenkins IH, Passingham RE, Nutt J, Frackowiak RS, Brooks DJ. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol 1992;32:151–161.
36.
Catalan MJ, Ishii K, Honda M, Samii A, Hallett M. A PET study of sequential finger movements of varying length in patients with Parkinson's disease. Brain 1999;122:483–495.
37.
Jenkins IH, Fernandez W, Playford ED, et al. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 1992;32:749–757.

Information & Authors

Information

Published In

Neurology®
Volume 68Number 13March 27, 2007
Pages: 1062-1068
PubMed: 17389313

Publication History

Published online: March 26, 2007
Published in print: March 27, 2007

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

N. Sawamoto, MD, PhD
From the Human Brain Research Center (N.S., M.H., T.H., T.A., M.I., H.F., H.S.), Kyoto University Graduate School of Medicine, Kyoto, Japan; Nano-Medicine Merger Education Unit (N.S.), Kyoto University, Kyoto, Japan; Department of Cortical Function Disorders (M.H., T.H.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; SORST (M.H.), Japan Science and Technology Agency, Kawaguchi, Japan; Laboratory of Cerebral Integration (H.T.), National Institute for Physiological Sciences, Okazaki, Japan; Department of Nuclear Medicine (H.T., K.I.), Kyoto University Graduate School of Medicine, Kyoto, Japan. Dr. Shibasaki is currently at Takeda General Hospital, Kyoto, Japan.
M. Honda, MD, PhD
From the Human Brain Research Center (N.S., M.H., T.H., T.A., M.I., H.F., H.S.), Kyoto University Graduate School of Medicine, Kyoto, Japan; Nano-Medicine Merger Education Unit (N.S.), Kyoto University, Kyoto, Japan; Department of Cortical Function Disorders (M.H., T.H.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; SORST (M.H.), Japan Science and Technology Agency, Kawaguchi, Japan; Laboratory of Cerebral Integration (H.T.), National Institute for Physiological Sciences, Okazaki, Japan; Department of Nuclear Medicine (H.T., K.I.), Kyoto University Graduate School of Medicine, Kyoto, Japan. Dr. Shibasaki is currently at Takeda General Hospital, Kyoto, Japan.
T. Hanakawa, MD, PhD
From the Human Brain Research Center (N.S., M.H., T.H., T.A., M.I., H.F., H.S.), Kyoto University Graduate School of Medicine, Kyoto, Japan; Nano-Medicine Merger Education Unit (N.S.), Kyoto University, Kyoto, Japan; Department of Cortical Function Disorders (M.H., T.H.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; SORST (M.H.), Japan Science and Technology Agency, Kawaguchi, Japan; Laboratory of Cerebral Integration (H.T.), National Institute for Physiological Sciences, Okazaki, Japan; Department of Nuclear Medicine (H.T., K.I.), Kyoto University Graduate School of Medicine, Kyoto, Japan. Dr. Shibasaki is currently at Takeda General Hospital, Kyoto, Japan.
T. Aso, MD
From the Human Brain Research Center (N.S., M.H., T.H., T.A., M.I., H.F., H.S.), Kyoto University Graduate School of Medicine, Kyoto, Japan; Nano-Medicine Merger Education Unit (N.S.), Kyoto University, Kyoto, Japan; Department of Cortical Function Disorders (M.H., T.H.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; SORST (M.H.), Japan Science and Technology Agency, Kawaguchi, Japan; Laboratory of Cerebral Integration (H.T.), National Institute for Physiological Sciences, Okazaki, Japan; Department of Nuclear Medicine (H.T., K.I.), Kyoto University Graduate School of Medicine, Kyoto, Japan. Dr. Shibasaki is currently at Takeda General Hospital, Kyoto, Japan.
M. Inoue, MD
From the Human Brain Research Center (N.S., M.H., T.H., T.A., M.I., H.F., H.S.), Kyoto University Graduate School of Medicine, Kyoto, Japan; Nano-Medicine Merger Education Unit (N.S.), Kyoto University, Kyoto, Japan; Department of Cortical Function Disorders (M.H., T.H.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; SORST (M.H.), Japan Science and Technology Agency, Kawaguchi, Japan; Laboratory of Cerebral Integration (H.T.), National Institute for Physiological Sciences, Okazaki, Japan; Department of Nuclear Medicine (H.T., K.I.), Kyoto University Graduate School of Medicine, Kyoto, Japan. Dr. Shibasaki is currently at Takeda General Hospital, Kyoto, Japan.
H. Toyoda, MD
From the Human Brain Research Center (N.S., M.H., T.H., T.A., M.I., H.F., H.S.), Kyoto University Graduate School of Medicine, Kyoto, Japan; Nano-Medicine Merger Education Unit (N.S.), Kyoto University, Kyoto, Japan; Department of Cortical Function Disorders (M.H., T.H.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; SORST (M.H.), Japan Science and Technology Agency, Kawaguchi, Japan; Laboratory of Cerebral Integration (H.T.), National Institute for Physiological Sciences, Okazaki, Japan; Department of Nuclear Medicine (H.T., K.I.), Kyoto University Graduate School of Medicine, Kyoto, Japan. Dr. Shibasaki is currently at Takeda General Hospital, Kyoto, Japan.
K. Ishizu, MD, PhD
From the Human Brain Research Center (N.S., M.H., T.H., T.A., M.I., H.F., H.S.), Kyoto University Graduate School of Medicine, Kyoto, Japan; Nano-Medicine Merger Education Unit (N.S.), Kyoto University, Kyoto, Japan; Department of Cortical Function Disorders (M.H., T.H.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; SORST (M.H.), Japan Science and Technology Agency, Kawaguchi, Japan; Laboratory of Cerebral Integration (H.T.), National Institute for Physiological Sciences, Okazaki, Japan; Department of Nuclear Medicine (H.T., K.I.), Kyoto University Graduate School of Medicine, Kyoto, Japan. Dr. Shibasaki is currently at Takeda General Hospital, Kyoto, Japan.
H. Fukuyama, MD, PhD
From the Human Brain Research Center (N.S., M.H., T.H., T.A., M.I., H.F., H.S.), Kyoto University Graduate School of Medicine, Kyoto, Japan; Nano-Medicine Merger Education Unit (N.S.), Kyoto University, Kyoto, Japan; Department of Cortical Function Disorders (M.H., T.H.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; SORST (M.H.), Japan Science and Technology Agency, Kawaguchi, Japan; Laboratory of Cerebral Integration (H.T.), National Institute for Physiological Sciences, Okazaki, Japan; Department of Nuclear Medicine (H.T., K.I.), Kyoto University Graduate School of Medicine, Kyoto, Japan. Dr. Shibasaki is currently at Takeda General Hospital, Kyoto, Japan.
H. Shibasaki, MD, PhD
From the Human Brain Research Center (N.S., M.H., T.H., T.A., M.I., H.F., H.S.), Kyoto University Graduate School of Medicine, Kyoto, Japan; Nano-Medicine Merger Education Unit (N.S.), Kyoto University, Kyoto, Japan; Department of Cortical Function Disorders (M.H., T.H.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; SORST (M.H.), Japan Science and Technology Agency, Kawaguchi, Japan; Laboratory of Cerebral Integration (H.T.), National Institute for Physiological Sciences, Okazaki, Japan; Department of Nuclear Medicine (H.T., K.I.), Kyoto University Graduate School of Medicine, Kyoto, Japan. Dr. Shibasaki is currently at Takeda General Hospital, Kyoto, Japan.

Notes

Address correspondence and reprint requests to Dr. Manabu Honda, Department of Cortical Function Disorders, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan; e-mail: [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Inhaling dementia: Environmental toxins, Alzheimer’s disease, and Parkinson’s disease, The Social Science Journal, (1-12), (2024).https://doi.org/10.1080/03623319.2024.2413785
    Crossref
  2. Blood transcriptomic signatures associated with molecular changes in the brain and clinical outcomes in Parkinson’s disease, Nature Communications, 14, 1, (2023).https://doi.org/10.1038/s41467-023-39652-6
    Crossref
  3. Cortical oscillatory dysfunction in Parkinson disease during movement activation and inhibition, PLOS ONE, 17, 3, (e0257711), (2022).https://doi.org/10.1371/journal.pone.0257711
    Crossref
  4. Gender based assessment of gait rhythms during dual-task in Parkinson’s disease and its early detection, Biomedical Signal Processing and Control, 72, (103346), (2022).https://doi.org/10.1016/j.bspc.2021.103346
    Crossref
  5. Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinson’s disease, Journal of Clinical and Experimental Neuropsychology, 43, 5, (469-480), (2021).https://doi.org/10.1080/13803395.2021.1927995
    Crossref
  6. A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease, Experimental Neurology, 335, (113514), (2021).https://doi.org/10.1016/j.expneurol.2020.113514
    Crossref
  7. Motor control, Principles and Practice of Movement Disorders, (52-69.e5), (2021).https://doi.org/10.1016/B978-0-323-31071-0.00002-0
    Crossref
  8. Gender Differences and Quality of Life in Parkinson’s Disease, International Journal of Environmental Research and Public Health, 18, 1, (198), (2020).https://doi.org/10.3390/ijerph18010198
    Crossref
  9. Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide Against Cognitive Decline in Neurodegenerative Diseases, Frontiers in Cellular Neuroscience, 14, (2020).https://doi.org/10.3389/fncel.2020.00221
    Crossref
  10. Functional correlates of cognitive slowing in Parkinson's disease, Parkinsonism & Related Disorders, 76, (3-9), (2020).https://doi.org/10.1016/j.parkreldis.2020.05.006
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share